NCT02171884

Brief Summary

For this project, 4 groups of 38 infants have been created so as to evaluate the impact of Assisted-Reproduction Technology (ART) and more particularly the two procedures classically used in ART: the freezing/thawing of embryos and prolonged embryo culture (five days of culture in appropriate in vitro conditions to allow development of the embryo) in contrast with shorter culture of only two days. Participation consists in accepting samples to be taken at the birth of the infant:

  1. 1.from the umbilical cord.
  2. 2.from the placenta.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
298

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2013

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 17, 2013

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

June 18, 2014

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 24, 2014

Completed
7.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 2, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 2, 2022

Completed
Last Updated

March 26, 2024

Status Verified

March 1, 2024

Enrollment Period

9.3 years

First QC Date

June 18, 2014

Last Update Submit

March 25, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Analysis of the expression of several genes subjected to imprinting (H19, IGF2, IGF2R, MEST, PEG3, SNRPN, IGF2, KCNQ1, GRB10 and PLAGL1)

    DNA / RNA extraction

    Baselines

  • Analysis of the expression of 3 transposable elements (HERV-K, LINE-1 and ALU)

    DNA / RNA extraction

    Baselines

  • Level of methylation and the level of expression of Genomic Imprinting (GI) and Transposable Elements (TE)

    DNA / RNA extraction

    Baselines

Study Arms (4)

Group E1

Singletons born following ART via IVF/ICSI (short culture)

Other: Sample of cord bloodOther: Sample of placenta

Group EC1

Singletons born following ART via IVF/ICSI and freezing-thawing of the embryo

Other: Sample of cord bloodOther: Sample of placenta

Group T1

Singletons conceived naturally

Other: Sample of cord bloodOther: Sample of placenta

Group E2

Singletons born following ART with IVF/ICSI (prolonged culture)

Other: Sample of cord bloodOther: Sample of placenta

Interventions

Group E1Group E2Group EC1Group T1
Group E1Group E2Group EC1Group T1

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

4 groups of infants: * conceived naturally * born following ART with IVF/ICSI (short culture) * born following ART with IVF/ICSI and freezing/thawing of the embryo * born following ART with IVF/ICSI (prolonged culture)

You may qualify if:

  • Patients who have provided written informed consent,
  • Patients with national health insurance cover,
  • Maternal age at conception between 20 and 43 years,
  • Paternal age at conception between 18 and 50 years,
  • Singleton pregnancy

You may not qualify if:

  • Maternal disease:
  • pulmonary, cardiac
  • renal and metabolic diseases (including type 1 and 2 diabetes prior to the pregnancy)
  • systemic inflammatory diseases
  • hypertension
  • neurological diseases
  • chronic hepatitis B or C
  • HIV infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHU de BESANCON

Besançon, 25030, France

Location

CHU de DIJON

Dijon, 21079, France

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 18, 2014

First Posted

June 24, 2014

Study Start

January 17, 2013

Primary Completion

May 2, 2022

Study Completion

May 2, 2022

Last Updated

March 26, 2024

Record last verified: 2024-03

Locations